September 17, 2013
|State||Number of Individuals on ADAP Waiting List||Percent of the Total ADAP Waiting List||Increase/Decrease From Previous Reporting Period||Date Waiting List Began|
|South Dakota||21||16%||+1||August 2012|
Note: ADAPs are required to recertify all enrolled clients at least twice a year. This process often creates limited slots below an ADAP enrollment cap. ADAPs often will not eliminate their waiting list until they are able to increase or remove the enrollment cap entirely.
The Senate's FY2014 budget includes an increase of $2 million over FY2012 for a total of $2.39 billion for the Ryan White Program, which includes a $10 million increase for the AIDS Drug Assistance Program (ADAP). Additionally, this total includes the President's 2011 World AIDS Day ADAP emergency relief funding (ERF) of $35 million. The Ryan White Part B base FY2014 funding was reduced by $1.5 million from FY2012 levels. The President's FY2014 budget request included an increase of $10 million for ADAP and it flat funded the Part B base from FY2012. The House budget never made it to the floor for a vote prior to the summer recess.
The FY2013 ERF funds have not yet been awarded to ADAPs. These funds are expected to be released by the end of this month. The FY2013 ERF funds consist of $65 million dollars in competing continuation funds for existing ERF grantees and $10 million in new competing funds available to ADAPs not previously receiving ERF. The budget period for these FY2013 ERF funds will be six months (through March 31, 2014) to allow future alignment of the FY2014 ADAP ERF (if funds are available) and FY2014 Part B base/ADAP earmark awards.
|Enrollment Cap||Expenditure Cap||Financial Eligibility||Formulary Reduction||Other|
New Mexico: monthly
South Dakota: annual
|Georgia: cap on insurance premiums
Montana: service reductions in place
|Expenditure Cap||Waiting List||Other|
|Washington: Stopped requiring use of PAPs during insurance enrollment|
West Virginia: Increased financial eligibility to 400%, up from 325%
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.